OncoMatch/Clinical Trials/NCT05753618
Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy
Is NCT05753618 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Granulocyte Colony-Stimulating Factor (G-CSF) and Omission of Granulocyte Colony-Stimulating Factor (G-CSF) for early-stage breast cancer.
Treatment: Granulocyte Colony-Stimulating Factor (G-CSF) · Omission of Granulocyte Colony-Stimulating Factor (G-CSF) — The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Excluded: Stage IV
early-stage or locally-advanced breast cancer; Metastatic cancer [excluded]
Prior therapy
Cannot have received: cytotoxic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify